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CORRESPONDENCE
Letter to the Editor
Dear Sir,
I depend on Seizure to publish informative articles
about new and old antiepileptic drugs as they repre-
sent the mainstay of therapy for my patients. Although
there are many other sources of information, such as
from the pharmaceutical companies and their repre-
sentatives, anecdotes from other healthcare providers,
and abstracts at scientific meetings, refereed journals
rank the highest. However, I have noticed a bias creep-
ing into the literature, of which the recent article by
Shorvon ‘Oxcarbazepine, a review’ Seizure 2000; 9:
75–79, is but one example.
He discusses common side-effects of the new AED
oxcarbazepine, including the 10% incidence of skin
rash, and the 20% incidence of SIADH (with sodium
as low or lower than 125 in 3%) with admonishments
that they are unimportant. Even recommending that
there is no need to monitor sodium except in special
cases. Other articles by other authors are equally dis-
dainful of complications such as the 1–2% incidence
of kidney stones with topiramate and zonisamide.
I for one cannot dismiss these complications. I rou-
tinely monitor serum sodium in my patients taking
carbamazepine and certainly will do so with oxcar-
bazepine; values less than 130 are unacceptable to me.
Even moderate hyponatremia causes some cognitive
and systemic effects such as headache, fatigue and
decreased concentration. I thought the goal of better
treatment was improved control and better quality of
life. Having had a kidney stone, I would not want to
offer this as a trade off for anything less than complete
and enduring seizure control.
Certainly physicians face a dilemma in using less
than perfect treatment modalities for their patients.
Articles need to present the pros and cons of therapy.
Is the glass half full or half empty? For academic jour-
nals it must be both. Realizing that there are two sides
(or more) to an issue, an author should acknowledge
both or all as objectively as possible and let the reader
determine how to apply this information to the patient.
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